CAJ | 학술논문

目的探讨罗格列酮联合胰岛素治疗2型糖尿病合并肺结核的疗效.方法对2型糖尿病合并肺结核66例患者在常规抗痨治疗的基础上,根据联合用药的不同,分为胰岛素组(DM+INS)33例,联合治疗组(DM+INS+RSG)33例,动态观察血糖、肺结核病灶及痰菌培养的情况.结果 DM+INS+RSG组不同时间痰菌阴转率均高于DM+INS组(X2=8.45,X2=6.11,X2=12.87,P<0.05),两组病灶吸收和空洞闭合差异均有统计学意义(X2=15.60,P<0.05;X2=5.00,P<0.05),DM+INS组治疗前后变化不明显;治疗后DM+INS+RSG组FPG、PPG和HbA1c较治疗前降低(P<0.05～0.01);与DM+INS组间比较差异有统计学意义(P<0.05～0.01).结论对单用胰岛素治疗血糖控制欠佳的2型糖尿病患者可加用胰岛素增敏剂罗格列酮治疗,可使血糖和糖化血红蛋白得以良好的控制.
목적 탐토라격렬동연합이도소치료2형당뇨병합병폐결핵적료효.방법 대2형당뇨병합병폐결핵66례환자재상규항로치료적기출상,근거연합용약적불동,분위이도소조(DM+INS)33례,연합치료조(DM+INS+RSG)33례,동태관찰혈당、폐결핵병조급담균배양적정황.결과 DM+INS+RSG조불동시간담균음전솔균고우DM+INS조(X2=8.45,X2=6.11,X2=12.87,P<0.05),량조병조흡수화공동폐합차이균유통계학의의(X2=15.60,P<0.05;X2=5.00,P<0.05),DM+INS조치료전후변화불명현;치료후DM+INS+RSG조FPG、PPG화HbA1c교치료전강저(P<0.05～0.01);여DM+INS조간비교차이유통계학의의(P<0.05～0.01).결론 대단용이도소치료혈당공제흠가적2형당뇨병환자가가용이도소증민제라격렬동치료,가사혈당화당화혈홍단백득이량호적공제.
Objective To observe rosiglitazone(RSG) combined with insulin therapy in type 2 diabetes pa-tients with tuberculosis. Methods 66 cases with type 2 diabetes and tuberculosis used the conventional antitubercu-losis treatment, divided into insulin group(DM + INS) 33 cases, the treatment group (DM + INS + RSG) 33 with dy-namic observation of blood glucose, and the lesions of tuberculosis in sputum culture. Results DM + INS + RSG group at the same time as the conversion rate is higher than DM + INS group(X2 = 8.45, X2 = 6.11,X2 = 12.87, P<0.05), the lesions were closed and empty absorption were significantly different (X2 = 15.60, P < 0.05 ; X2 = 5.00, P< 0.05), DM + INS group before and after treatment did not change significantly. After treatment DM + INS + RSGgroup FPG, PPG and HbAlc levels lower than before treatment(P < 0.05～0.01 ) and DM + INS group with sig-nificant differences( P < 0.05～0.01 ). Conclusion The addition of rosiglitazone to insulin treatment results in sig-nificantly improvement in glycemic control in the type 2 diabetic patients.